Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.

อุตสาหกรรม

Biotechnology

ภาคส่วน

Healthcare

สำนักงานใหญ่

CN

ซีอีโอ

Youzhi Tong

จดทะเบียนตั้งแต่

22 พ.ค. 2563

พนักงาน

123